Variability of radioiodine measurements in the thyroid

A comparison between GATE4 results and MCNP4B published data for internal radiation dosimetry

Aim: GATE, has been designed as upper layer of the GEANT4 toolkit for nuclear medicine application including internal dosimetry. However, its results have not been fully compared to the well-developed codes and anthropomorphic voxel phantoms have never been used with GATE/GEANT for internal dosimetry. The aim of present study was to compare the internal dose calculated by GATE/GEANT with the MCNP4B published data. Methods: The Zubal phantom was used to model a typical adult male. Activity was assumed uniformly distributed in liver, kidneys, lungs, spleen, pancreas and adrenals. GATE/ GEANT Monte Carlo package was used for estimation of doses in the phantom. Simulations were performed for photon energy of 0.01–1 MeV and mono-energetic electrons of 935 keV. Specific absorbed fractions for photons and S-factors for electrons were calculated. Results: On average, GATE/GEANT produces higher photon SAF (Specific Absorbed Fraction) values (+2.7%) for self-absorption and lower values (-2.9%) for cross-absorption. The difference was higher for paired organs particularly lungs. Moreover the photon SAF values for lungs as source organ at the energy of 200 and 500 keV was considerably higher with MCNP4B compared to GATE. Conclusion: Despite of differences between the GATE4 and MCNP4B, the results can be considered ensuring. This may be considered as validation of GATE/GEANT as a proprietary code in nuclear medicine for radionuclide dosimetry applications.

NUMERICAL ASSESSMENT OF 131I DEPOSITED IN THYROID FOR NON-STANDARD SITUATIONS

At the CIEMAT whole-body counter, a low-energy germanium detector is used for the in vivo assessment of (131)I activity in thyroid, mainly for the individual monitoring programmes of workers. The detector is calibrated with a cylindrical neck phantom made of polymethyl methacrylate that mimics the neck of an adult, containing a vial with a radioactive solution. For an accurate activity assessment, it is necessary to perform the calibration of the detector with phantoms that closely reproduce the anatomy of a real person. Nevertheless, it is not affordable to count on a variety of physical phantoms covering the different anatomical characteristics that could be found over the whole population, including children. An alternative approach to face this situation is offered by the numerical calibration procedure based on Monte Carlo calculations in conjunction with realistic voxel phantoms. A series of computational voxel phantoms of different ages and dimensions have been used in this work to simulate an internal contamination of the thyroid and to estimate the response of the detector for measurements involving individuals whose anatomical characteristics differ from the reference adult man.

A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy

PURPOSE

In the radiopharmaceutical therapy approach to the fight against cancer, in particular when it comes to translating laboratory results to the clinical setting, modeling has served as an invaluable tool for guidance and for understanding the processes operating at the cellular level and how these relate to macroscopic observables. Tumor control probability (TCP) is the dosimetric end point quantity of choice which relates to experimental and clinical data: it requires knowledge of individual cellular absorbed doses since it depends on the assessment of the treatment's ability to kill each and every cell. Macroscopic tumors, seen in both clinical and experimental studies, contain too many cells to be modeled individually in Monte Carlo simulation; yet, in particular for low ratios of decays to cells, a cell-based model that does not smooth away statistical considerations associated with low activity is a necessity. The authors present here an adaptation of the simple sphere-based model from which cellular level dosimetry for macroscopic tumors and their end point quantities, such as TCP, may be extrapolated more reliably.

METHODS

Ten homogenous spheres representing tumors of different sizes were constructed in GEANT4. The radionuclide 131I was randomly allowed to decay for each model size and for seven different ratios of number of decays to number of cells, N(r): 1000, 500, 200, 100, 50, 20, and 10 decays per cell. The deposited energy was collected in radial bins and divided by the bin mass to obtain the average bin absorbed dose. To simulate a cellular model, the number of cells present in each bin was calculated and an absorbed dose attributed to each cell equal to the bin average absorbed dose with a randomly determined adjustment based on a Gaussian probability distribution with a width equal to the statistical uncertainty consistent with the ratio of decays to cells, i.e., equal to Nr-1/2. From dose volume histograms the surviving fraction of cells, equivalent uniform dose (EUD), and TCP for the different scenarios were calculated. Comparably sized spherical models containing individual spherical cells (15 microm diameter) in hexagonal lattices were constructed, and Monte Carlo simulations were executed for all the same previous scenarios. The dosimetric quantities were calculated and compared to the adjusted simple sphere model results. The model was then applied to the Bortezomib-induced enzyme-targeted radiotherapy (BETR) strategy of targeting Epstein-Barr virus (EBV)-expressing cancers.

RESULTS

The TCP values were comparable to within 2% between the adjusted simple sphere and full cellular models. Additionally, models were generated for a nonuniform distribution of activity, and results were compared between the adjusted spherical and cellular models with similar comparability. The TCP values from the experimental macroscopic tumor results were consistent with the experimental observations for BETR-treated 1 g EBV-expressing lymphoma tumors in mice.

CONCLUSIONS

The adjusted spherical model presented here provides more accurate TCP values than simple spheres, on par with full cellular Monte Carlo simulations while maintaining the simplicity of the simple sphere model. This model provides a basis for complementing and understanding laboratory and clinical results pertaining to radiopharmaceutical therapy.